

CLSTN3 antibody - N-terminal region
Rabbit Polyclonal Antibody
Catalog # AI12745

Specification

CLSTN3 antibody - N-terminal region - Product Information

Application	WB
Primary Accession	Q9BOT9
Other Accession	NM_014718 , NP_055533
Reactivity	Human, Mouse, Rat, Rabbit, Pig, Horse, Bovine, Guinea Pig, Dog
Predicted	Human, Mouse, Rat, Chicken, Guinea Pig
Host	Rabbit
Clonality	Polyclonal
Calculated MW	106kDa KDa

CLSTN3 antibody - N-terminal region - Additional Information

Gene ID 9746

Alias Symbol [CSTN3](#), [KIAA0726](#), [MGC131797](#), [MGC138488](#), [alcbeta](#), [CDHR14](#)

Other Names

Calsyntenin-3, Alcadein-beta, Alc-beta, CLSTN3, CS3, KIAA0726

Format

Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.

Reconstitution & Storage

Add 50 ul of distilled water. Final anti-CLSTN3 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.

Precautions

CLSTN3 antibody - N-terminal region is for research use only and not for use in diagnostic or therapeutic procedures.

CLSTN3 antibody - N-terminal region - Protein Information

Name CLSTN3 {ECO:0000303|PubMed:33101212, ECO:0000312|HGNC:HGNC:18371}

Function

Postsynaptic adhesion molecule that binds to presynaptic neurexins to mediate both excitatory and inhibitory synapse formation (PubMed:25352602). Promotes synapse development by acting as a cell adhesion molecule at the postsynaptic membrane, which associates with both neurexin-alpha and neurexin-beta proteins at the presynaptic membrane (PubMed:25352602). Regulates the balance between excitatory and inhibitory synapses by inhibiting formation of excitatory

parallel-fiber synapses and promoting formation of inhibitory synapses in the same neuron (By similarity). May also be involved in ascorbate (vitamin C) uptake via its interaction with SLC23A2/SVCT2 (PubMed:34673103). Complex formation with APBA2 and APP, stabilizes APP metabolism and enhances APBA2-mediated suppression of beta-APP40 secretion, due to the retardation of intracellular APP maturation (Probable) (PubMed:12972431).

Cellular Location

Postsynaptic cell membrane {ECO:0000250|UniProtKB:Q99JH7}; Single-pass type I membrane protein. Endoplasmic reticulum membrane {ECO:0000250|UniProtKB:Q99JH7}; Single-pass type I membrane protein. Golgi apparatus membrane {ECO:0000250|UniProtKB:Q99JH7}; Single-pass type I membrane protein. Cell projection, dendrite {ECO:0000250|UniProtKB:Q99JH7}. Note=Most prominent in the postsynaptic specializations of asymmetric (type I) synapses with both axodendritic and axospinous localization {ECO:0000250|UniProtKB:Q99JH7}

Tissue Location


According to PubMed:12498782, expressed predominantly in the brain and in kidney (PubMed:12498782). Low levels in heart, skeletal muscle, liver, placenta, pancreas and lung (PubMed:12498782). According to PubMed:12972431, predominant expression in brain, and only marginal in kidney (PubMed:12972431). In brain, present throughout all cortical layers, highest levels in GABAergic neurons (based on morphology and distribution pattern) (PubMed:12972431).

CLSTN3 antibody - N-terminal region - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

CLSTN3 antibody - N-terminal region - Images



WB Suggested Anti-CLSTN3 Antibody Titration: 0.2-1 µg/ml

ELISA Titer: 1:62500

Positive Control: RPMI 8226 cell lysate